Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma
- PMID: 19638909
- DOI: 10.1097/SLA.0b013e3181b0c80e
Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma
Abstract
Objective: This prospective randomized multicenter study aims to evaluate the efficacy of extensive intraoperative peritoneal lavage followed by intraperitoneal chemotherapy (EIPL-IPC) on the overall 5-year survival of advanced gastric cancer patients with intraperitoneal free cancer cells without overt peritoneal metastasis (CY+/P-). The study also aims to determine the merit and reliability of EIPL-IPC therapy as a prophylactic strategy for peritoneal metastasis.
Summary background data: Although the prognosis of advanced gastric cancer patients with CY+/P- is extremely poor, a suitable standard regimen for treating such patients has not yet been established.
Methods: A total of 88 patients with CY+/P- from 1522 patients with advanced gastric cancer at multicenters were enrolled in this study and were randomly allocated to 3 groups: surgery alone group, surgery plus intraperitoneal chemotherapy (IPC) group, and surgery plus EIPL and IPC (EIPL-IPC) group. Prognostic significance of EIPL-IPC therapy was evaluated by Kaplan-Meier curves, and its value as an independent prognostic factor was assessed by univariate and multivariate analyses.
Results: The overall 5-year survival rate of the patients with EIPL-IPC was 43.8%, and this data were significantly better than that of the IPC group (4.6%, P < 0.0001) and the surgery alone group (0%, P < 0.0001). Among various recurrent patterns, the EIPL-IPC group had a significantly lower incidence of peritoneal recurrence than both of the other groups (P < 0.0001). Univariate and multivariate analyses revealed that EIPL was the most significant impact factor.
Conclusions: The present study clearly revealed that EIPL-IPC therapy significantly improved the 5-year survival span of advanced gastric cancer patients with CY+/P-. Thus, EIPL-IPC therapy is strongly recommended as a standard prophylactic strategy for peritoneal dissemination.
Similar articles
-
Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial.Lancet Gastroenterol Hepatol. 2021 Feb;6(2):120-127. doi: 10.1016/S2468-1253(20)30315-0. Epub 2020 Nov 27. Lancet Gastroenterol Hepatol. 2021. PMID: 33253659 Clinical Trial.
-
The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients.Int J Clin Oncol. 2016 Apr;21(2):289-294. doi: 10.1007/s10147-015-0892-6. Epub 2015 Aug 22. Int J Clin Oncol. 2016. PMID: 26296529
-
Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Trial.JAMA Surg. 2019 Jul 1;154(7):610-616. doi: 10.1001/jamasurg.2019.0153. JAMA Surg. 2019. PMID: 30916742 Free PMC article. Clinical Trial.
-
Efficacy and Safety of Extensive Intraperitoneal Lavage for Patients with Gastric Cancer - A Systematic Review and Meta-analysis.J Gastrointest Cancer. 2024 Mar;55(1):96-104. doi: 10.1007/s12029-023-00971-y. Epub 2023 Sep 26. J Gastrointest Cancer. 2024. PMID: 37750984
-
The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches.J Invest Surg. 2017 Oct;30(5):318-324. doi: 10.1080/08941939.2016.1247930. Epub 2016 Nov 2. J Invest Surg. 2017. PMID: 27806214 Review.
Cited by
-
Molecular Cytology by One-Step Nucleic Acid Amplification (OSNA) Assay of Peritoneal Washings during D2 Gastrectomy in Advanced Gastric Cancer Patients: Preliminary Results.J Clin Med. 2021 Nov 10;10(22):5230. doi: 10.3390/jcm10225230. J Clin Med. 2021. PMID: 34830512 Free PMC article.
-
Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2).Pleura Peritoneum. 2016 Sep 1;1(3):159-166. doi: 10.1515/pp-2016-0017. Epub 2016 Sep 20. Pleura Peritoneum. 2016. PMID: 30911619 Free PMC article.
-
Low density neutrophils (LDN) in postoperative abdominal cavity assist the peritoneal recurrence through the production of neutrophil extracellular traps (NETs).Sci Rep. 2018 Jan 12;8(1):632. doi: 10.1038/s41598-017-19091-2. Sci Rep. 2018. PMID: 29330531 Free PMC article.
-
Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer.Transl Gastroenterol Hepatol. 2016 Sep 19;1:69. doi: 10.21037/tgh.2016.08.03. eCollection 2016. Transl Gastroenterol Hepatol. 2016. PMID: 28138635 Free PMC article. Review.
-
Survival outcomes and prognostic indicators for gastric cancer patients with positive peritoneal wash cytology but no peritoneal metastasis after radical gastrectomy.World J Gastrointest Oncol. 2021 Jan 15;13(1):24-36. doi: 10.4251/wjgo.v13.i1.24. World J Gastrointest Oncol. 2021. PMID: 33510847 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical